Entries by wp_art_ad-biotech

New website!

ARTES has launched a new website, incorporating new content to give a better view on the current business and added offer. The new site especially features an overview of ARTES’ business expansion in technology transfer and its Metavax® approach for VLP-based vaccine development.

Strategic cooperation between ARTES Biotechnology and PAC

Artes and PAC join forces and combine their technologies and know-how. ARTES Biotechnology specializes in recombinant protein production, process development in microbial expression systems and is a technology provider for pharmaceutical processes, while PAC (Peschek Analytic Consulting) is highly skilled in the field of protein analysis and quality control. Together with PAC, ARTES will now […]

Strategic collaboration deal for vaccine development

ARTES Biotechnology, specialized in recombinant protein production and process development in microbial expression systems, started a development collaboration for two vaccines together with global biopharma-ceutical company Crucell. Crucell is focused on the research & development, production and marketing of vaccines and antibodies against infectious disease worldwide. Aim of the long-term research cooperation is a new-product […]

ARTES and NL join in a strategic collaboration and co-marketing alliance

ARTES, specialized in recom-binant protein production and process development from yeast expression systems and the US based company NL Biotech-nologies, owner and specialized in certain tech-nologies for production of vaccines and diagnostic proteins started a strategic collaboration. With signing this collaboration agreement the two companies combine their know-how and technologies in yeast expres-sion, process and […]

New Scientific Board Member

Prof. PhD David Anderson Burnet Institute, Melbourne, Australia, Deputy Director, Burnet Senior Principal Fellow. Professor Anderson is an expert in Microbiology and Molecular Virology. He has focused his work on understanding the structure and assembly of hepatitis viruses, and the use of this information to design better diagnostics, vaccines and antiviral therapies for control of […]

BIO 2011, Washington DC

Meet us at the partnering “Business Forum” event of the Bio International Convention 2011 in Washington DC or contact us directly for a personal meeting! The Bio 2011 is taking place from June 27 – 30. Go to BIO website

ARTES steps further into the vaccine business by acquiring Anavax

ARTES Biotechnology announces today the acquirement of the ANAVAX virus-like particle (VLP) technology from Select Vaccines Ltd. ANAVAX is a patent-protected VLP technology that can be applied to the prevention of several infectious diseases. With the combination of two excellent technology platforms, ANAVAX and the Hansenula expression system, ARTES has positioned itself as a unique […]

Injectable Sustained Release Formulations of Therapeutic Proteins

Q Chip Ltd and ARTES Biotechnology GmbH announce that they have signed a Collaborative Agreement to explore the co-development of a new sustained release formulation of interferon alpha 2a for the treatment of chronic hepatitis B and C. The study is designed to evaluate Q Chip’s Q-Sphera™ peptide and protein delivery platform to develop a […]

ARTES and Rhein Minapharm continue their successful product development collaboration

Langenfeld and Cairo – ARTES Biotechnology and Rhein Minapharm Biogenetics jointly announced the successful production of a new target of a therapeutic protein. This is the first result of a long-term research collaboration that was signed in January 2008. Consequently, the two companies extended their collaboration in May 2009. ARTES applied its proprietary Hansenula technology […]

ARTES is research partner of ChemBioTec project supported by Deutsche Stiftung Umwelt

ARTES Biotechnology today announces the collaboration with 5 other collaboration partners in a joint 28 months research program that is granted by the national Deutsche Stiftung Umwelt within the ChemBioTec initiative. The Deutsche Bundesstiftung Umwelt DBU is one of Europe’s largest foundations and promotes innovative and exemplary environmental projects The funded project includes three academic […]